Lyell Immunopharma

Lyell Immunopharma: Series C Funding Round

Lyell Immunopharma has successfully raised $425M in Series C funding, reaching a valuation of $1.4B.

Company Overview

T-cell reprogramming for solid tumors

Funding Details

The Series C round was led by GV, with participation from F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb.

Company Information

• Headquarters: 201 Haskins Way, South San Francisco, CA 94080
• Founded: 2018
• Employees: 300+
• Category: Biotech

Investment

Lyell Immunopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• GV: Verified investor in Series C
• F-Prime Capital: Verified investor in Series C
• Bain Capital Life Sciences: Verified investor in Series C
• Patient Square Capital: Verified investor in Series C
• Bristol Myers Squibb: Verified investor in Series C